A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

This study is for adults aged 18 and over who have recently been diagnosed with multiple myeloma. You would need to have already had some initial treatment for your myeloma (usually 4 to 6 cycles) and that treatment must have helped to stabilise or improve your condition. You also need to be generally well and fit enough to have a high-dose chemotherapy followed by a stem cell transplant.

There are certain health conditions that would mean you couldn't join the study. For example, if your myeloma has spread to your brain or spinal cord, or if you have certain other serious medical problems. Also, if you've had specific types of cell therapy or targeted treatments in the past, you might not be able to take part.

If you join this study, it's a long-term commitment. The study itself could last up to 13 years for everyone involved. For you personally, if you receive the AZD0120 treatment, you'll be followed up for a total of 15 years after your treatment infusion.

Treatment involves different steps depending on which group you're in. If you receive AZD0120, you'll have 3 days of preparation, a single day for the AZD0120 infusion, and then you'll take a maintenance medicine called lenalidomide for up to 2 years. If you're in the stem cell transplant group, you'll have 1-2 days of preparation, the stem cell transplant, and then up to 2 years of lenalidomide maintenance medicine. This is an 'open-label' study, meaning both you and your doctors will know which treatment you are receiving, and you'll be randomly assigned to one of the two treatment groups.